AstraZeneca shares climb after earnings beat estimates as cancer drug portfolio drives strong growth

Wait 5 sec.

Adjusted earnings per share, excluding certain items, climbed 21% to $2.63 in the latest quarter, comfortably surpassing analysts' expectations